DK0588917T3 - Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion - Google Patents
Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktionInfo
- Publication number
- DK0588917T3 DK0588917T3 DK92912971T DK92912971T DK0588917T3 DK 0588917 T3 DK0588917 T3 DK 0588917T3 DK 92912971 T DK92912971 T DK 92912971T DK 92912971 T DK92912971 T DK 92912971T DK 0588917 T3 DK0588917 T3 DK 0588917T3
- Authority
- DK
- Denmark
- Prior art keywords
- isoxazole
- cognitive function
- enhance cognitive
- treatment
- isothiazole compounds
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title 1
- 150000003854 isothiazoles Chemical class 0.000 title 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
- OLROCKKMZHTZFM-UHFFFAOYSA-N 1,2-oxazole;1,2-thiazole Chemical compound C=1C=NOC=1.C=1C=NSC=1 OLROCKKMZHTZFM-UHFFFAOYSA-N 0.000 abstract 1
- 206010001605 Alcohol poisoning Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000003554 absence epilepsy Diseases 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000006949 cholinergic function Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70692091A | 1991-05-29 | 1991-05-29 | |
| PCT/US1992/004631 WO1992021339A1 (fr) | 1991-05-29 | 1992-05-28 | Composes d'isoxazole et d'isothiazole ameliorant les fonctions cognitives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0588917T3 true DK0588917T3 (da) | 2001-02-12 |
Family
ID=24839628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK92912971T DK0588917T3 (da) | 1991-05-29 | 1992-05-28 | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5409946A (fr) |
| EP (1) | EP0588917B1 (fr) |
| JP (1) | JP3153551B2 (fr) |
| AT (1) | ATE197454T1 (fr) |
| BR (1) | BR1100981A (fr) |
| CA (1) | CA2109585C (fr) |
| DE (1) | DE69231557T2 (fr) |
| DK (1) | DK0588917T3 (fr) |
| ES (1) | ES2153360T3 (fr) |
| GR (1) | GR3035285T3 (fr) |
| IE (1) | IE921690A1 (fr) |
| PT (1) | PT100525B (fr) |
| WO (1) | WO1992021339A1 (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU678186B2 (en) * | 1992-10-23 | 1997-05-22 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
| US5424444A (en) * | 1992-11-25 | 1995-06-13 | Abbott Laboratories | Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles |
| US5494680A (en) * | 1993-12-08 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Transdermal delivery device |
| US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
| US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
| US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| DE19501022C1 (de) * | 1995-01-14 | 1996-06-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung |
| WO1996030372A1 (fr) * | 1995-03-24 | 1996-10-03 | Japan Tobacco Inc. | Derives diazabicyclo[3.3.1]nonane et leurs intermediaires, leur application therapeutique et procedes de production |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
| US5723414A (en) * | 1996-01-24 | 1998-03-03 | Rohm And Haas Company | 5-aryl-isoxazolinones and herbicidal use thereof |
| WO1997040011A1 (fr) | 1996-04-23 | 1997-10-30 | R. J. Reynolds Tobacco Company | Preparations pharmaceutiques pour la prevention et le traitement de troubles du systeme nerveux central |
| US5706829A (en) * | 1996-06-06 | 1998-01-13 | Creighton University | Method for treating neurocardiogenic syncope |
| US6166032A (en) * | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| ATE229509T1 (de) | 1997-05-30 | 2002-12-15 | Neurosearch As | Azacyclooktan- und heptan-derivate, ihre herstellung und ihre therapeutische verwendung |
| HUP0002713A3 (en) | 1997-05-30 | 2001-02-28 | Neurosearch As | 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use |
| CN1205210C (zh) * | 1997-05-30 | 2005-06-08 | 神经研究公司 | 作为尼古丁ACh受体上胆碱能配体的9－氮杂双环(3.3.1)壬－2－烯衍生物 |
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| US6133002A (en) | 1997-09-25 | 2000-10-17 | Dsm N.V. | Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| WO2001068104A1 (fr) * | 2000-03-16 | 2001-09-20 | The Mclean Hospital Corporation | Composes servant a traiter des troubles psychiatriques ou des troubles provoques par la consommation abusive de substances psychoactives |
| BR0316054A (pt) * | 2002-11-08 | 2005-09-20 | Mclean Hospital Corp | Compostos para tratamento de dependência e privação de tabaco |
| CA2508995A1 (fr) * | 2002-12-20 | 2004-07-15 | The Mclean Hospital Corporation | Composes pour la normalisation du cycle sommeil/etat de veille |
| US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
| AU2004317087A1 (en) * | 2003-10-08 | 2005-09-22 | The Mclean Hospital Corporation | Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| CA2539811A1 (fr) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Compositions pharmaceutiques et methodes destinees au soulagement de la douleur et au traitement de troubles du systeme nerveux central |
| FR2862647B1 (fr) * | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| EP1765364A4 (fr) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | Pyrimidines, tels que cytidine, dans les traitements de patients souffrant de troubles bipolaires |
| US7737128B2 (en) * | 2004-06-10 | 2010-06-15 | The Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
| WO2006020703A1 (fr) * | 2004-08-11 | 2006-02-23 | The Mclean Hospital Corporation | Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana |
| CA2580329C (fr) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Administration de medicament transdermique biosynchrone |
| EP1977746B8 (fr) | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Procédés et compositions pour la réduction des effets indésirables de traitements thérapeutiques |
| US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
| WO2010030887A1 (fr) * | 2008-09-11 | 2010-03-18 | Catholic Healthcare West | Atténuation nicotinique d’une inflammation du snc et de l’auto-immunité |
| WO2011085406A1 (fr) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Composés et compositions pour l'amélioration de la cognition, leurs procédés de fabrication, et méthodes de traitement |
| WO2012033956A1 (fr) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Composés et compositions améliorant la cognition, méthodes de préparation et méthodes de traitement |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| JP6114841B2 (ja) | 2013-02-28 | 2017-04-12 | ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． | グリコピロレート塩 |
| CA2974324A1 (fr) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Procedes et systemes d'administration de medicament |
| EP3565617A1 (fr) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Dispositifs et methodes d'administration transdermique de medicament |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (fr) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Systeme d'administration transdermique de medicaments a regulation thermique |
-
1992
- 1992-05-28 EP EP92912971A patent/EP0588917B1/fr not_active Expired - Lifetime
- 1992-05-28 DE DE69231557T patent/DE69231557T2/de not_active Expired - Lifetime
- 1992-05-28 AT AT92912971T patent/ATE197454T1/de not_active IP Right Cessation
- 1992-05-28 JP JP50062493A patent/JP3153551B2/ja not_active Expired - Fee Related
- 1992-05-28 ES ES92912971T patent/ES2153360T3/es not_active Expired - Lifetime
- 1992-05-28 CA CA002109585A patent/CA2109585C/fr not_active Expired - Lifetime
- 1992-05-28 PT PT100525A patent/PT100525B/pt active IP Right Grant
- 1992-05-28 DK DK92912971T patent/DK0588917T3/da active
- 1992-05-28 WO PCT/US1992/004631 patent/WO1992021339A1/fr not_active Ceased
- 1992-07-01 IE IE169092A patent/IE921690A1/en not_active IP Right Cessation
-
1993
- 1993-09-08 US US08/118,079 patent/US5409946A/en not_active Expired - Lifetime
-
1997
- 1997-05-14 BR BR1100981-0A patent/BR1100981A/pt active IP Right Grant
-
2001
- 2001-01-24 GR GR20010400099T patent/GR3035285T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69231557D1 (de) | 2000-12-14 |
| BR1100981A (pt) | 2000-04-18 |
| ES2153360T3 (es) | 2001-03-01 |
| ATE197454T1 (de) | 2000-11-11 |
| CA2109585A1 (fr) | 1992-12-10 |
| IE921690A1 (en) | 1992-12-02 |
| JP3153551B2 (ja) | 2001-04-09 |
| PT100525A (pt) | 1993-09-30 |
| US5409946A (en) | 1995-04-25 |
| GR3035285T3 (en) | 2001-04-30 |
| EP0588917B1 (fr) | 2000-11-08 |
| PT100525B (pt) | 1999-10-29 |
| DE69231557T2 (de) | 2001-06-21 |
| CA2109585C (fr) | 2000-02-15 |
| WO1992021339A1 (fr) | 1992-12-10 |
| EP0588917A1 (fr) | 1994-03-30 |
| JPH06508143A (ja) | 1994-09-14 |
| EP0588917A4 (fr) | 1994-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0588917T3 (da) | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion | |
| DK0663912T3 (da) | Heterocykliske etherforbindelser til forstærkning af den kognitive funktion | |
| DE3263734D1 (en) | Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (z), their preparation and their use as medicines in the treatment of disorders of the central nervous system | |
| BG102173A (en) | Aromatic compounds and pharmaceutical compositions containing them | |
| KR950702829A (ko) | 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체 | |
| NO960380D0 (no) | Middel til behandling av neurosykdommer | |
| FI931888A0 (fi) | Kramploesande cykliska fruktopyranossulfiter -och sulfater | |
| WO2003031435A8 (fr) | Derives pyrazole inhibiteurs de transport de glycine | |
| DE69528485D1 (de) | Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel | |
| ZA842185B (en) | New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof | |
| HUT66971A (en) | 4-amino-naphthyridine derivatives pharmaceutical compositions containing the same and process for the production of thereof | |
| ATE170530T1 (de) | Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten | |
| IL111275A0 (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments | |
| MY132077A (en) | Use of n-substituted phenothiazines for the production of medicaments, novel substances and a process for their preparation | |
| ATE140450T1 (de) | Neue n-benzoylprolin-derivate, verfahren zur herstellung und diese enthaltende arzneimittel | |
| AR028802A1 (es) | El uso de ciertos compuestos de ftalazina para el tratamiento de enfermedades neovasculares oculares | |
| NO973342L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer | |
| DE69625709D1 (de) | Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten | |
| NO980531L (no) | Medikament for å hemme avhengighet og toleranse utviklet ved narkotisk smertestillende middel | |
| SE8503109D0 (sv) | Cyclic prodrugs of antiinflammatory oxicams | |
| ATE5408T1 (de) | Cephalosporine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| AU1621392A (en) | New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them | |
| GR3015592T3 (en) | Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases. | |
| ATE181331T1 (de) | Salmycine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| NO943793L (no) | Ny anvendelse av |